Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 3/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | WDR5 | P61964 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.52 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ufiprazole SCHEMBL29455226 | 1.00 | BRS3 (0.84) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL7929368 | 0.99 | BRS3 (0.82) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL7950477 | 0.99 | BRS3 (0.82) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL31529606 | 0.99 | BRS3 (0.82) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL3180530 | 0.95 | BRS3 (0.76) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL3170203 | 0.94 | BRS3 (0.74) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL12873280 | 0.93 | BRS3 (0.73) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL3186458 | 0.92 | BRS3 (0.71) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL1816535 | 0.91 | BRS3 (1.00) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Ufiprazole SCHEMBL29693729 | 0.91 | BRS3 (1.00) | BRS3CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271289-A | Preparation method of esomeprazole sodium | 苏州东瑞制药有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-114478481-B | Preparation method of omeprazole | 扬州大学 | 2024-04-02 | — | — | CN | claimed |
| CN-115305243-B | Baeyer-Villiger monooxygenase mutant and application thereof | 江南大学 | 2023-06-02 | — | — | CN | claimed |
| CN-115044566-B | Cyclohexanone monooxygenase mutant and application thereof | 江南大学 | 2023-05-02 | — | — | CN | claimed |
| CN-115305243-A | Baeyer-Villiger monooxygenase mutant and application thereof | 江南大学 | 2022-11-08 | — | — | CN | claimed |
| CN-112255352-B | Method for detecting related substances of esomeprazole sodium for injection | 海南卫康制药(潜山)有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-115044566-A | Cyclohexanone monooxygenase mutant and application thereof | 江南大学 | 2022-09-13 | — | — | CN | claimed |
| US-20220267742-A1 | NADPH-REGENERATION SYSTEM BASED ON MONOMERIC ISOCITRATE DEHYDROGENASE AND USE THEREOF | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2022-08-25 | — | — | US | claimed |
| US-11236309-B2 | Recombinant vector and method for producing reconstituted cytochrome P450 oxygenase-reductase fusion protein using the same | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2022-02-01 | — | — | US | claimed |
| US-20220016099-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | TRINUERO (KR) | 2022-01-20 | — | — | US | claimed |
| EP-0931076-A1 | METHOD OF OMEPRAZOLE PREPARATION | Slovakofarma, A.S. (SK) | 1999-07-28 | — | — | EP | claimed |
| WO-1999025711-A1 | NEW PROCESS | ASTRA AKTIEBOLAG (SE) | 1999-05-27 | — | — | WO | claimed |
| WO-1998054171-A1 | NOVEL FORM OF S-OMEPRAZOLE | ASTRA AKTIEBOLAG (SE) | 1998-12-03 | — | — | WO | claimed |
| WO-1998009962-A1 | METHOD OF OMEPRAZOLE PREPARATION | SLOVAKOFARMA, A.S. (SK) | 1998-03-12 | — | — | WO | claimed |
| EP-0533752-B1 | IMPROVED METHOD FOR SYNTHESIS | ASTRA AB (SE) | 1998-01-28 | — | — | EP | claimed |
| US-5578732-A | MONO-OXIDATION OF SULFUR ATOM BY HYDROGEN PEROXIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-11-26 | — | — | US | claimed |
| US-5386032-A | Method of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazole (omeprazole) | AKTIEBOLAGET ASTRA (SE) | 1995-01-31 | — | — | US | claimed |
| EP-0533752-A1 | IMPROVED METHOD FOR SYNTHESIS | Astra Aktiebolag (SE) | 1993-03-31 | — | — | EP | claimed |
| EP-0484265-A1 | A process for the preparation of omeprazol | CENTRO GENESIS PARA LA INVESTIGACION, S.L. (ES) | 1992-05-06 | — | — | EP | claimed |
| WO-1991018895-A1 | IMPROVED METHOD FOR SYNTHESIS | AKTIEBOLAGET ASTRA (SE) | 1991-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016099-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | KEAP1, SLC5A1, GCLC | BRS3 2502/4885CYP2C9 1053/4885CYP2C19 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.